Novartis Pelacarsen Phase 3 Trial Fails; Royalty Pharma Expects to Recoup $500M
Question
Novartis Pelacarsen Phase 3 Trial Fails; Royalty Pharma Expects to Recoup $500M
Direct answer
Novartis experienced a major pipeline setback as topline results from the Phase 3 HORIZON trial showed pelacarsen failed to significantly reduce cardiovascular events in patients with elevated lipoprotein(a). Royalty Pharma, which funded $500 million toward the program, clarified that its contractual structure protects the initial principal and is expected to deliver a modest positive return despite the clinical miss. — bearish pressure on NVS.
- Original publisher
- Market Ontology
- Evidence through
- 2026-09-05
- Published
- 2026-10-20
- Revision
- 1 · 2026-10-20
Cite as: Market Ontology, “Novartis Pelacarsen Phase 3 Trial Fails; Royalty Pharma Expects to Recoup $500M”, revision 1, evidence through 2026-09-05. https://marketontology.com/catalysts/2026-09-05/novartis-pelacarsen-phase-3-trial-fails-royalty-pharma-expects-to-recoup-500m-cea1da
| Asset | Direction | Timeframe | Channel | Score |
|---|---|---|---|---|
| NVS | ▼Bear | 1–5 days | Macro Repricing | 63 |
Novartis Pelacarsen Phase 3 Trial Fails; Royalty Pharma Expects to Recoup $500M
Novartis experienced a major pipeline setback as topline results from the Phase 3 HORIZON trial showed pelacarsen failed to significantly reduce cardiovascular events in patients with elevated lipoprotein(a). Royalty Pharma, which funded $500 million toward the program, clarified that its contractual structure protects the initial principal and is expected to deliver a modest positive return despite the clinical miss. — bearish pressure on NVS.
Novartis experienced a major pipeline setback as topline results from the Phase 3 HORIZON trial showed pelacarsen failed to significantly reduce cardiovascular events in patients with elevated lipoprotein(a). Royalty Pharma, which funded $500 million toward the program, clarified that its contractual structure protects the initial principal and is expected to deliver a modest positive return despite the clinical miss.
- SummaryNovartis experienced a major pipeline setback as topline results from the Phase 3 HORIZON trial showed pelacarsen failed to significantly reduce cardiovascular events in patients with elevated lipoprotein(a). Royalty Pharma, which funded $500 million toward the program, clarified that its contractual structure protects the initial principal and is expected to deliver a modest positive return despite the clinical miss.
- NVSDirect directional or hedged short
Illustrative, not advice
- Crowded positioning may already reflect the move
- Counter-catalyst could neutralize the thesis before window closes
- Fed officials or competing data may reframe the print
- NVS closes above pre-catalyst level on rising volume
- Catalyst narrative is officially walked back or contradicted
- Cross-asset confirmation (rates / FX / vol) reverses direction
- NVS price vs. pre-event level
- NVS volume vs. 20-day average
- 2Y/10Y Treasury yield direction
- DXY direction
- Fed funds futures repricing
What happened next
Price follow-up pending — no stored daily closes for these assets yet.
Closing prices from stored daily bars; returns measured from the last close on or before the event date. Not a recommendation.
No verifiable public source recorded for this card.
Related catalysts
- 2026-09-16CAR-T oncology market expands as ALL and lymphoma therapies target long-term growthAUTL GILD NVS
- 2026-09-16CAR-T oncology market expands as ALL and lymphoma therapies target long-term growthAUTL GILD NVS
- 2026-09-05Novartis Pelacarsen Phase 3 Trial Fails; Royalty Pharma Expects to Recoup $500MNVS RPRX
- 2026-09-05Novartis Phase 3 Pelacarsen Trial Fails Primary Cardiovascular EndpointNVS
- 2026-09-05Novartis Phase 3 Pelacarsen Cardiovascular Trial Misses Primary EndpointNVS RPRX
- 2026-09-05Novartis Phase 3 Pelacarsen Trial Fails Primary Cardiovascular EndpointIONS NVS RPRX-11.45%
- 2026-09-05Novartis Phase 3 Pelacarsen Trial Fails Primary Cardiovascular EndpointIONS NVS-11.45%
- 2026-09-01Novartis Remibrutinib Meets Primary Endpoint in Phase III MS TrialNVS
See today's live cards
Public pages are published 24 hours after the product shows them. Desk shows every catalyst, event and causal reading as it happens, mapped to your holdings.